Almitas Capital LLC Design Therapeutics, Inc. Transaction History
Almitas Capital LLC
- $214 Million
- Q3 2024
A detailed history of Almitas Capital LLC transactions in Design Therapeutics, Inc. stock. As of the latest transaction made, Almitas Capital LLC holds 1,323,667 shares of DSGN stock, worth $6.42 Million. This represents 3.32% of its overall portfolio holdings.
Number of Shares
1,323,667
Previous 1,253,248
5.62%
Holding current value
$6.42 Million
Previous $4.2 Million
69.63%
% of portfolio
3.32%
Previous 1.82%
Shares
3 transactions
Others Institutions Holding DSGN
# of Institutions
103Shares Held
30.8MCall Options Held
2.3KPut Options Held
16.5K-
Sr One Capital Management, LP6.53MShares$31.7 Million11.88% of portfolio
-
Logos Global Management LP San Francisco, CA4.22MShares$20.5 Million3.0% of portfolio
-
Black Rock Inc. New York, NY2.3MShares$11.2 Million0.0% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA1.89MShares$9.18 Million0.55% of portfolio
-
Baker Bros. Advisors LP New York, NY1.74MShares$8.46 Million0.1% of portfolio
About Design Therapeutics, Inc.
- Ticker DSGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 55,807,900
- Market Cap $271M
- Description
- Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions. The company's portfolio of products comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ syste...